Skip to main content
PDSB
NASDAQ Life Sciences

PDS Biotech Seeks 1-for-10 to 1-for-35 Reverse Split to Hold Nasdaq Listing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.782
Mkt Cap
$81.631M
52W Low
$0.195
52W High
$1.79
52W Position info
301% above low
Off High info
56% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

PDSB has more than doubled off its 52-week low of $0.195 on light trading volume (0.1× avg).

Summary

PDS Biotech is asking shareholders to approve a reverse split of 1-for-10 to 1-for-35, executable at Board discretion through 2027, to cure a Nasdaq bid-price deficiency that must be resolved by January 26, 2027. The authorized share count is not reduced, so the split would sharply expand the pool of shares the company can issue.


Key Events · Corporate Governance and Compliance · PDSB

  • Reverse Split Range Set at 1-for-10 to 1-for-35

    At a special meeting scheduled for December 2026, holders will be asked to approve a reverse split at a ratio the Board selects within 1-for-10 to 1-for-35, exercisable any time on or before December 31, 2027.

  • Authorized Shares Stay at 300 Million

    Because the split does not reduce the 300,000,000 authorized shares, authorized-but-unissued and unreserved stock would rise from 123,047,504 to 294,944,217 at a 1-for-35 ratio — a much larger pool available for future issuance.

  • Nasdaq Cure Deadline January 26, 2027

    Nasdaq issued a minimum bid deficiency notice on July 30, 2026 after 30 straight days below $1.00; the stock closed at $0.8073 on November 19, 2026, and the initial 180-day period ends January 26, 2027.

  • No Second Compliance Period After a Split

    Under Nasdaq Rule 5810(c)(3)(A)(iv), if the stock fails the $1.00 bid test within one year after a reverse split, Nasdaq will issue a delisting determination with no further cure period.


Analysis · PDSB · Life Sciences

PDS closed at $0.8073 on November 19, 2026, below Nasdaq's $1.00 minimum bid, and has until January 26, 2027 to cure the deficiency. The proxy asks holders to pre-authorize a reverse split the Board can execute at any ratio from 1-for-10 to 1-for-35 through December 31, 2027. The critical detail is that the 300,000,000 authorized share count stays intact: at a 1-for-35 ratio, authorized-but-unissued and unreserved shares would jump from 123,047,504 to 294,944,217, giving management a far larger pool to issue into a company that already carries a going-concern warning and a $50M ATM. A split fixes the listing arithmetic but not the underlying cash position, and Nasdaq will not grant another compliance period if the stock slips back under $1.00 within a year of the split.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PDSB was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.6M. The 52-week trading range was $0.20 to $1.79. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PDSB - Latest Insights

PDSB
Nov 13, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9822
Real-time Price: $0.785 info
Change: -$0.1972 (-20%) info
Market Cap: $81.631M info
PDSB
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $0.785 info
Change: -$0.295 (-27%) info
Market Cap: $81.631M info
PDSB
Oct 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9521
Real-time Price: $0.785 info
Change: -$0.1671 (-18%) info
Market Cap: $81.631M info
PDSB
Oct 14, 2026, 4:17 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.785 info
Change: -$0.625 (-44%) info
Market Cap: $81.631M info
PDSB
Sep 22, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8334
Real-time Price: $0.785 info
Change: -$0.0484 (-6%) info
Market Cap: $81.631M info